Biglycan potentially regulates angiogenesis during fracture repair by altering expression and function of endostatin

Matrix Biology

Volumn 52-54, Issue , 2016, Pages 141-150

  Myren, Maja ^a   Kirby, David J ^a   Noonan, Megan L ^a   Maeda, Azusa ^a   Owens, Rick T ^b   Ricard Blum, Sylvie ^c   Kram, Vardit ^a   Kilts, Tina M ^a   Young, Marian F ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b LIFECELL CORPORATION   (United States)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Angiogenesis; Biglycan; Endostatin; Fracture healing

Indexed keywords

BIGLYCAN; ENDOSTATIN; SURAMIN; VASCULOTROPIN; BGN PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD VESSEL PARAMETERS; CALLUS; CELL GROWTH; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; ENCHONDRAL OSSIFICATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; THREE DIMENSIONAL IMAGING; VASCULARIZATION; VESSEL LENGTH; VESSEL THICKNESS; WILD TYPE; ANIMAL; CYTOLOGY; DOWN REGULATION; FRACTURE HEALING; GENE INACTIVATION; GENETICS; METABOLISM;

ANIMALS; BIGLYCAN; COMPUTED TOMOGRAPHY ANGIOGRAPHY; DOWN-REGULATION; ENDOSTATINS; ENDOTHELIAL CELLS; FRACTURE HEALING; GENE KNOCKOUT TECHNIQUES; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; X-RAY MICROTOMOGRAPHY;

EID: 84970015911     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2016.03.008     Document Type: Review

References (37)

1. Berendsen A.D., Pinnow E.L., Maeda A., Brown A.C., McCartney-Francis N., Kram V., Owens R.T., Robey P.G., Holmbeck K., de Castro L.F., Kilts T.M., Young M.F. Biglycan modulates angiogenesis and bone formation during fracture healing. Matrix Biol. J. Int. Soc. Matrix Biol. 2014, 35:223-231.
2. Donaldson L.J., Cook A., Thomson R.G. Incidence of fractures in a geographically defined population. J. Epidemiol. Community Health 1990, 44:241-245.
3. Donaldson L.J., Reckless I.P., Scholes S., Mindell J.S., Shelton N.J. The epidemiology of fractures in England. J. Epidemiol. Community Health 2008, 62:174-180.
4. Moucha C.S., Einhorn T.A. Bone Morphogenetic proteins and other growth factors to enhance fracture healing and treatment of nonunions. Bone Regeneration and Repair: Biology and Clinical Applications 2005, 169. Humana Press, Totowa, New Jersey. J.R. Lieberman, G.E. Friedlaender (Eds.).
5. Santolini E., West R., Giannoudis P.V. Risk factors for long bone fracture non-union: a stratification approach based on the level of the existing scientific evidence. Injury 2015, 46(Suppl. 8):S8-S19.
6. Iozzo R.V., Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. J. Int. Soc. Matrix Biol. 2015, 42:11-55.
7. Xu T., Bianco P., Fisher L.W., Longenecker G., Smith E., Goldstein S., Bonadio J., Boskey A., Heegaard A.M., Sommer B., Satomura K., Dominguez P., Zhao C., Kulkarni A.B., Robey P.G., Young M.F. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 1998, 20:78-82.
8. Chen X.D., Shi S., Xu T., Robey P.G., Young M.F. Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2002, 17:331-340.
9. Corsi A., Xu T., Chen X.D., Boyde A., Liang J., Mankani M., Sommer B., Iozzo R.V., Eichstetter I., Robey P.G., Bianco P., Young M.F. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2002, 17:1180-1189.
10. Ameye L., Aria D., Jepsen K., Oldberg A., Xu T., Young M.F. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2002, 16:673-680.
11. Goldberg M., Septier D., Rapoport O., Iozzo R.V., Young M.F., Ameye L.G. Targeted disruption of two small leucine-rich proteoglycans, biglycan and decorin, excerpts divergent effects on enamel and dentin formation. Calcif. Tissue Int. 2005, 77:297-310.
12. Chen X.D., Fisher L.W., Robey P.G., Young M.F. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004, 18:948-958.
13. Berendsen A.D., Fisher L.W., Kilts T.M., Owens R.T., Robey P.G., Gutkind J.S., Young M.F. Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17022-17027.
14. Walia A., Yang J.F., Huang Y.H., Rosenblatt M.I., Chang J.H., Azar D.T. Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim. Biophys. Acta 2015, 1850:2422-2438.
15. Zeng X., Chen J., Miller Y.I., Javaherian K., Moulton K.S. Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis. J. Lipid Res. 2005, 46:1849-1859.
16. Zhang L., Ge W., Hu K., Zhang Y., Li C., Xu X., He D., Zhao Z., Zhang J., Jie F., Chen Y., Zheng Y. Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol. Biol. Rep. 2012, 39:89-95.
17. Dixelius J., Cross M.J., Matsumoto T., Claesson-Welsh L. Endostatin action and intracellular signaling: beta-catenin as a potential target?. Cancer Lett. 2003, 196:1-12.
18. Parris G.E. A hypothesis concerning the biphasic dose-response of tumors to angiostatin and endostatin. Dose-Response Publ. Int. Hormesis Soc. 2015, 13.
19. Hu L., Duan Y.T., Li J.F., Su L.P., Yan M., Zhu Z.G., Liu B.Y., Yang Q.M. Biglycan enhances gastric cancer invasion by activating FAK signaling pathway. Oncotarget 2014, 5:1885-1896.
20. Yamamoto K., Ohga N., Hida Y., Maishi N., Kawamoto T., Kitayama K., Akiyama K., Osawa T., Kondoh M., Matsuda K., Onodera Y., Fujie M., Kaga K., Hirano S., Shinohara N., Shindoh M., Hida K. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br. J. Cancer 2012, 106:1214-1223.
21. Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., Folkman J., Hlatky L., Huber P.E. Endostatin's antiangiogenic signaling network. Mol. Cell 2004, 13:649-663.
22. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., Pihlajaniemi T., Alitalo K., Vuori K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1024-1029.
23. Ferreras M., Felbor U., Lenhard T., Olsen B.R., Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000, 486:247-251.
24. Sipola A., Seppinen L., Pihlajaniemi T., Tuukkanen J. Endostatin affects osteoblast behavior in vitro, but collagen XVIII/endostatin is not essential for skeletal development in vivo. Calcif. Tissue Int. 2009, 85:412-420.
25. Neill T., Schaefer L., Iozzo R.V. Decorin as a multivalent therapeutic agent against cancer. Adv. Drug Deliv. Rev. 2015.
26. Neill T., Schaefer L., Iozzo R.V. Decoding the matrix: Instructive roles of proteoglycan receptors. Biochemistry 2015, 54:4583-4598.
27. Iozzo R.V., Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. 2010, 277:3864-3875.
28. Behl T., Kotwani A. Possible role of endostatin in the antiangiogenic therapy of diabetic retinopathy. Life Sci. 2015, 135:131-137.
29. Yuasa M., Mignemi N.A., Barnett J.V., Cates J.M., Nyman J.S., Okawa A., Yoshii T., Schwartz H.S., Stutz C.M., Schoenecker J.G. The temporal and spatial development of vascularity in a healing displaced fracture. Bone 2014, 67:208-221.
30. Goyal A., Neill T., Owens R.T., Schaefer L., Iozzo R.V. Decorin activates AMPK, an energy sensor kinase, to induce autophagy in endothelial cells. Matrix Biol. J. Int. Soc. Matrix Biol. 2014, 34:46-54.
31. Poluzzi C., Iozzo R.V., Schaefer L. Endostatin and Endorepellin: A Common Route of Action for Similar Angiostatic Cancer Avengers 2015, Advanced drug delivery reviews.
32. Moreth K., Frey H., Hubo M., Zeng-Brouwers J., Nastase M.V., Hsieh L.T., Haceni R., Pfeilschifter J., Iozzo R.V., Schaefer L. Biglycan-triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury. Matrix Biol. J. Int. Soc. Matrix Biol. 2014, 35:143-151.
33. Claes L., Recknagel S., Ignatius A. Fracture healing under healthy and inflammatory conditions. Nat. Rev. Rheumatol. 2012, 8:133-143.
34. Schaefer L., Babelova A., Kiss E., Hausser H.J., Baliova M., Krzyzankova M., Marsche G., Young M.F., Mihalik D., Gotte M., Malle E., Schaefer R.M., Grone H.J. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 2005, 115:2223-2233.
35. Muller R., Koller B., Hildebrand T., Laib A., Gianolini S., Ruegsegger P. Resolution dependency of microstructural properties of cancellous bone based on three-dimensional mu-tomography. Technology Health Care Off. J. Eur. Soc. Eng. Med. 1996, 4:113-119.
36. Hildebrand T., Laib A., Muller R., Dequeker J., Ruegsegger P. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1999, 14:1167-1174.
37. Faye C., Inforzato A., Bignon M., Hartmann D.J., Muller L., Ballut L., Olsen B.R., Day A.J., Ricard-Blum S. Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells. Biochem. J. 2010, 427:467-475.